pleased of any financial recent and morning, some to for Good to thanks Thanks, Rob. be quarter then questions. review joining everyone, and 'XX take we'd updates, results to for the first us our cover
is infection. candidate to trial Xb compared randomized ibezapolstat, lead X:X with ibezapolstat care double our our patients trial first difficile of of Xb quarter, the blind non-inferiority we In C. treatment the a oral more trial treat standard oral to although enroll infection of oral difficile for of C. to patients a in vancomycin, Phase our clinical continued antibiotic
endpoint a day primary trial, of sustained trial. end is treatment and this measured The the follow-up known won't results at is the double-blind at until XX Since is end endpoint cure secondary the of visit. clinical be cure clinical a
signals However, as be and the has between been operationally, In includes Xb comparing observed ibezapolstat trial date conducted no microbiome blinded the further exceptional. non-inferiority safety the to is an has to to vanco exploratory data vanco. The superiority. expected the reported ibezapolstat of analysis with impact proceeding phase trial for and will the event protocol on demonstrated test endpoint
clinical and to trial XX the sites than have aftermath, expected slower its in the from expanded a total to we during now number enrolment Xb we participating COVID-XX sites. the XX the Due initial of trial Phase trial of sites
an we've Most in reaching had which either recall, early you enrolled XX our the allow recommendation We completing patients second which trial, importantly in to to March FDA the of to as Xb will provide amendment the data accepted Xa review committee, patients enrollment IND, trial continue and clinical interim the of assembled monitoring its anticipate protocol XXXX, our enrolling. done we the may or terminate independent with half 'XX. data upon XX alternatively to then
diff impact antibiotic company of available review. to long each microbiome, we conducts of interim the data dual managing therapy. believe which term exceptional while about after for we has the excited this properly the to infection report particularly care ibezapolstat The intends is IDMC The remain C. appropriately company - patient's treat
Denmark. the Conference 'XX some the quarter from two in XX ECCMID were first include presentations cases shortly 'XX, of highlights Copenhagen, Other or following. In key at the thereafter in April made Annual
and Chair, presented clinical program. aspects Pharmacology and to was C. and by Isolates Garey, of Houston difficile with ibezapolstat microbiome of of difficile-directed Reduced C. of scientific a trial University Susceptibility entitled Professor Against our College for Antibiotics" First, poster Susceptibility Principal "Novel Dr. Pharmacy, Ibezapolstat Investigator Kevin
that it action to its and capability susceptibility Garey only strains also its positive the was susceptible were C. fidaxomicin in work of anti-virulence also to mechanisms, cause Garey's DNA IIIC. noted Ibezapolstat's in reduced fact meaning unique virulence metronidazole, pol Dr. finding effect, C. inhibiting but the disease. diff action ibezapolstat's flagellar some is movement to mechanism demonstrated difficile organism inhibit reflecting of to not of namely reduced C. mode vanco bacterial a diff ibezapolstat. of unexpected Dr. target that will
presented preclinical antibacterial DRSP Chairman, The at treatment research. second update by Ursula positive Executive of oral featured the other MRSA, the company's DeLuccia, at of regarding renowned IV our who an our by and microbiology Chairman, for corner, gram and organized pipeline a infections Dr. ECCMID Bob Theuretzbacher, systemic expert session ECCMID two VRE in the by caused Presentation was program world
no validation in the the and Following and XXX% solubility presentation binding in significant cytotoxicity, poster and and of website. are number and vivo in with target in a our of clinical Phase re-infections, showing made the infection safety we've demonstrated oral the efficacy bacterial on vitro, Both IV pol cures mouse our in available Xa improvements trial have protein IIIC models.
evaluate previously with a Holland Additionally, inhibitors a million government Dutch sponsorship, continued mention action we and for the IV grant Leiden the to under $X.X the infections. of positive pipeline University wanted gram company mechanism systemic the antibiotic the bacterial our in its is Dutch against Medical which DNA awarded pol IIIC of collaboration of oral to target approximately treatment, of further from has our of R&D the bacterial Center enzyme
we're was Data a in would the regard, the if hoping But successful we're more additional in generated application it for describe research component. based on this grant and an to the grant receive I'll second collaboration, middle which critical detail in to recent non-dilutive CARB-X, this moment. of a to include in program through, from $XXX,XXX in more for of expecting two-year in this it year be comes range which this
second of this the our the year. of in funding no CARB-X. we infections targeting treatment October Let's than expect decision We antibiotic CARB-X final turn now MRSA a later by candidate and to running for remain
this to came targeting on million October CARB-X the to our grant of X of antibiotic $XX.X for for infections if funding to Phase five program trials. applied to a 'XX, second Just we approved non-dilutive period for how in up which years would of reflect up MRSA about provide a of start clinical
to already understanding is having believe no us active recently XX. by our under unique candidates, recent the that progress final application pool review our the CARB-X the a CARB-X together that of informed is later rendered decision on than final class We that remain most October made on and review. based be decisions and CARB-X of nature active antibiotics we new with development in our
we $XX that strong possibility for later ACX-XXX. oral IV million have CARB-X in believe and these For antibiotic $XX.X funding and reasons, million to year. project of If the of the approval fund a gain would will a candidate approved, we formulations CARB-X second cover our
later Now public in meeting a year innovations convene the Congress World-Antimicrobial AMR both to Resistance the in weigh the September, where field private Congress just ahead in latest from AMR. this looking the experts and annual in sectors bit will on Philadelphia, address its
next for section was for available presentation, and DeLuccia showcase Bob novel Executive pandemic. bacterial of present will the After Innovative the be an it at Our gram-positive IIIC will to entitled infections invited DNA will speak conference our preparing on the the inhibitors Chairman update and poly website.
to antibiotics the a is ahead the Act. month, pioneering infections, Senators S. subscription like Bennet end resistance. Act, encourage antimicrobial and the innovative to threatening bit, Todd needed. development use most Last improve ensure an mention domestic reintroduced of looking targeting from PASTEUR of antibiotics appropriate searching and To we'd Also PASTEUR availability U. when drug the Colorado Michael Young, up
PASTEUR Bennett, antibiotics strengthen and antibiotic failures, pipeline next will ever strongest the Act and save the development fix is our Senator to bill lives. written for the generation expand bipartisan use. market It According to
sponsors potential Act for as enhance Phase PASTEUR health target antibiotic if public that U.S. is candidates, the prospects antimicrobial commercial in would by stockpiling under year antibiotics facilities for If as threatening prospects in lead case drafted into approved, currently our serious of antibiotics each candidate a passed our providing the Act ibezapolstat. at X life the or as our for need our of PASTEUR enthusiastic to approved years, to infections a XX class the the to new with of of apply trials treatment antibiotic and clinical antibiotic designation PASTEUR the funding about the critical X Accordingly, being quite has are a Act which we're law.
financial our to the quarter. of highlights back Shawah, Rob? our results for you through CFO, Now guide to the Rob
